ATE292983T1 - Chimäres retrovirus/adenovirus system - Google Patents

Chimäres retrovirus/adenovirus system

Info

Publication number
ATE292983T1
ATE292983T1 AT97948396T AT97948396T ATE292983T1 AT E292983 T1 ATE292983 T1 AT E292983T1 AT 97948396 T AT97948396 T AT 97948396T AT 97948396 T AT97948396 T AT 97948396T AT E292983 T1 ATE292983 T1 AT E292983T1
Authority
AT
Austria
Prior art keywords
retroviral
vector
functions
chimeric
cells
Prior art date
Application number
AT97948396T
Other languages
English (en)
Inventor
David T Curiel
Original Assignee
Univ Alabama Birmingham Res Fo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alabama Birmingham Res Fo filed Critical Univ Alabama Birmingham Res Fo
Application granted granted Critical
Publication of ATE292983T1 publication Critical patent/ATE292983T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT97948396T 1996-11-19 1997-11-19 Chimäres retrovirus/adenovirus system ATE292983T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3132396P 1996-11-19 1996-11-19
US3708197P 1997-02-04 1997-02-04
PCT/US1997/021169 WO1998022143A1 (en) 1996-11-19 1997-11-19 Chimeric retrovirus/adenovirus system

Publications (1)

Publication Number Publication Date
ATE292983T1 true ATE292983T1 (de) 2005-04-15

Family

ID=26707084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948396T ATE292983T1 (de) 1996-11-19 1997-11-19 Chimäres retrovirus/adenovirus system

Country Status (8)

Country Link
US (1) US6333030B1 (de)
EP (1) EP0956052B1 (de)
JP (1) JP4214239B2 (de)
AT (1) ATE292983T1 (de)
AU (1) AU728610B2 (de)
CA (1) CA2272121A1 (de)
DE (1) DE69733035T2 (de)
WO (1) WO1998022143A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434594T2 (de) * 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US20060275261A1 (en) * 1993-10-25 2006-12-07 Canji, Inc. Adenoviral vectors having a protein IX deletion
US20010006629A1 (en) * 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US8703480B1 (en) 1997-03-21 2014-04-22 Enzo Therapeutics, Inc. Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
EP1005561A4 (de) * 1997-03-21 2004-03-31 Enzo Therapeutics Inc A Fully Vektor, virale vektoren und verpackungszelllinien zur deren vermehrung
AU6962698A (en) * 1997-04-11 1998-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Transgenomic viruses and the use thereof
AU2796799A (en) * 1998-03-03 1999-09-20 Uab Research Foundation, The Amplification of gene transfer and gene therapy by controlled replication
US20060183228A1 (en) * 1998-03-24 2006-08-17 Enzo Therapeutics, Inc. Viral vectors with surface or envelope components
FR2778670B1 (fr) 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
WO2000017376A1 (en) * 1998-09-22 2000-03-30 The Governement Of The United States Of America, As Represented By The Secretary Of The Departement Of Health And Human Services Replication deficient retroviral vector system and methods of using
WO2001055362A2 (en) 2000-01-31 2001-08-02 The Governement Of The United States Of America, As Represented By The Secretary, Departement Of Health & Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
ATE444372T1 (de) 2000-05-31 2009-10-15 Human Gene Therapy Res Inst Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
JP2005526001A (ja) * 2001-10-04 2005-09-02 アグイラルーコルドバ，カリオス，エスツアルド 遺伝子療法用キメラ型ウイルスベクター
US20070037284A1 (en) * 2003-06-04 2007-02-15 Enzo Therapeutics, Inc. Vectors for expressing exogenous gene or exogenous nucleic acid sequences
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
US12612444B2 (en) 2019-11-26 2026-04-28 University of Pittsburgh—of the Commonwealth System of Higher Education T cell receptors targeting mutations in RNA splicing factors
WO2021158962A2 (en) 2020-02-06 2021-08-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education T cell receptors targeting defective dna repair proteins
US10822379B1 (en) 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1695197A (en) * 1996-01-05 1997-08-01 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors

Also Published As

Publication number Publication date
EP0956052A4 (de) 2001-05-02
CA2272121A1 (en) 1998-05-28
DE69733035D1 (en) 2005-05-19
DE69733035T2 (de) 2005-11-24
AU5447598A (en) 1998-06-10
US6333030B1 (en) 2001-12-25
WO1998022143A1 (en) 1998-05-28
JP4214239B2 (ja) 2009-01-28
JP2001509009A (ja) 2001-07-10
EP0956052B1 (de) 2005-04-13
AU728610B2 (en) 2001-01-11
EP0956052A1 (de) 1999-11-17

Similar Documents

Publication Publication Date Title
DE69733035D1 (en) Chimäres retrovirus/adenovirus system
Feng et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector
AU737801B2 (en) Lentiviral vectors
US6323031B1 (en) Lentiviral vectors derived from SIVagm, methods for their preparation and their use for gene transfer into mammalian cells
US7303910B2 (en) Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
US20060177934A1 (en) Lentiviral LTR-deleted vector
NZ500740A (en) Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
WO1993010218A1 (en) Vectors including foreign genes and negative selective markers
JP2001517452A5 (de)
Pizzato et al. Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer
Konopka et al. Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication
EP1244797A4 (de) Fusionsprotein verabreichungssystem und dessen verwendungen
US20020034393A1 (en) Vector
US20080124308A1 (en) Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins
Mergia et al. The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs
AU758155B2 (en) Construction of retroviral producer cells from adenoviral and retroviral vectors
DK0880594T3 (da) Retroviral vektor og dens anvendelse i genterapi
Cannon et al. Retroviral vectors for gene therapy
KR20020003215A (ko) 기능성 및 비기능성 스플라이스 도너와 스플라이스 억셉터사이트로 구성된 레트로바이러스 벡터
US6130089A (en) Materials and methods for gene transfer
CA2331440A1 (en) Amphotropic retrovirus packaging cell line, process for its production and use thereof
Blomberg et al. Gene therapy of monogenic and cardiovascular disorders
Gibson et al. Delivery of tumor suppressor genes to reverse the malignant phenotype
Suzuki et al. Infection of human cells by murine ecotropic viruses: retroviral vectors carrying the hygromycin resistance-encoding gene
Sedlacek et al. Somatic Gene Therapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties